Analyst firms · Morgan Stanley · BILI

Morgan Stanley BILI price target and rating history

Bilibili Inc. (BILI) · Technology

Morgan Stanley rates Bilibili Inc. (BILI) Overweight with a $31 price target, as of its latest action on Apr 13, 2026. It has published 3 rating actions on BILI since January 2022, including 1 upgrade and 1 downgrade. Across 4 firms with a BILI price target in the last 12 months, the median target is $25. Morgan Stanley's $31 is 24% above that.

Current rating
Overweight
Price target
$31
Median target, all firms
$25
Actions on BILI
3

Morgan Stanley price target on BILI

$31$23$152023202420252026
Morgan Stanley price target on BILI, each point a stated target, January 2022 to April 2026. Targets before September 2024 (divided by 3) are adjusted for a stock split, going by the prior target Morgan Stanley restated.

Every Morgan Stanley rating on BILI

How other firms rate BILI

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
MacquarieNeutral$13.90Nov 16, 2026
BNP Paribas ExaneOutperform$23Sep 22, 2026
Morgan StanleyOverweight$31Apr 13, 2026
CitigroupBuy$27Mar 27, 2026

Questions about Morgan Stanley and BILI

What is Morgan Stanley's price target for BILI?
Morgan Stanley's latest stated price target for Bilibili Inc. (BILI) is $31, from its action on Apr 13, 2026.
What is Morgan Stanley's rating on BILI?
Morgan Stanley rates BILI Overweight, a bullish rating, as of Apr 13, 2026.
When did Morgan Stanley last change its view on BILI?
On Apr 13, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $31.
How does Morgan Stanley's BILI target compare with other analysts?
Across 4 firms with a BILI price target in the last 12 months, the median target is $25. Morgan Stanley's $31 is 24% above that.

More BILI rating histories

All Morgan Stanley ratingsBILI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.